IL-23 inhibitor topped ustekinumab against psoriasis

SAN FRANCISCO – An investigational interleukin-23 inhibitor for moderate to severe plaque psoriasis achieved almost twice the PASI 90 response rate of ustekinumab and generated no major safety signals, based on data from randomized trial of...
Source: Skin and Allergy News - Category: Dermatology Tags: CME-candidate RHEUM Conference News SAN Clinical News SAN News RHEUM News IMN News IMN Dermatology RHEUM Psoriatic arthritis Source Type: news